Aegerion Pharmaceuticals (AEGR) Misses Q3 EPS by 6c, Lowers JUXTAPID Guidance

Sex, Drugs and Aegerion (AEGR)

Aegerion Pharmaceuticals (NASDAQ: AEGR) shares plunged an unprecedented 41% on Friday after the maker of cholesterol lowering drug JUXTAPID reported disappointing third quarter results and lowered 2014 JUXTAPID net product sales guidance to between $150 and $160 million versus its previous expectations of $180 and $200 million.

While... More

BofA/Merrill Lynch Downgrades Aegerion Pharmaceuticals (AEGR) to Underperform

BofA/Merrill Lynch downgraded Aegerion Pharmaceuticals (NASDAQ: AEGR) from Buy to Underperform with a price target of $28.00 (from $48.00).

For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.

Shares of Aegerion Pharmaceuticals closed at $34.21 yesterday.

Needham & Company Downgrades Aegerion Pharmaceuticals (AEGR) to Hold

Needham & Company downgraded Aegerion Pharmaceuticals (NASDAQ: AEGR) from Buy to Hold.

Analyst Chad Messer commented, "Aegerion reported disappointing 3Q:14 Juxtapid sales, lowered 2014 guidance, and introduced a lackluster sales forecast for 2015. Much higher than expected patient drop out rates appear to be the biggest... More

Jefferies Downgrades Aegerion Pharmaceuticals (AEGR) to Hold

Jefferies downgraded Aegerion Pharmaceuticals (NASDAQ: AEGR) from Buy to Hold with a price target of $24.00 (from $61.00).

Analyst Eun K. Yang comments, "Despite the complexities of ultra-orphan drug launch & learning curve, 2x miss in sales/2x downward revisions in FY14 guidance (by ~5%/18%) leave little room... More

Deutsche Bank Downgrades Aegerion Pharmaceuticals (AEGR) to Hold

Deutsche Bank downgraded Aegerion Pharmaceuticals (NASDAQ: AEGR) from Buy to Hold with a price target of $26.00 (from $58.00).

Analyst Robyn Karnauskas said, "The co missed Q3 Juxtapid revs by $5M ($44M vs. $49M consensus) and decreased guidance significantly to $150-160M... More

JPMorgan Downgrades Aegerion Pharmaceuticals (AEGR) to Neutral

JPMorgan downgraded Aegerion Pharmaceuticals (NASDAQ: AEGR) from Overweight to Neutral with a price target of $23.00 (from $48.00).

For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.

Shares of Aegerion Pharmaceuticals closed at $34.21 yesterday.